Literature DB >> 19231532

ISL-1 is induced in stomach mesenchyme in the presence of pancreatic epithelia.

Autumn M Rowan-Hull1, Roheet Rao, Stuart A Robertson, Paul R V Johnson.   

Abstract

BACKGROUND/
PURPOSE: beta-Cell replacement offers a potential cure for type 1 diabetes mellitus in children. We have previously shown that stomach mesenchyme (SM) is competent to derive islet tissue by mesenchymal-to-epithelial transition (iMET). The aim of this study was to further characterize the developmental fate of this SM in the presence of pancreatic epithelia (PE) in SM/PE recombinants. The homeobox ISL-1 was examined in these recombinants because this gene is restricted to the dorsal pancreatic mesenchyme and endocrine cells in early pancreatic development.
METHODS: Chick-quail recombinants of SM + PE (n = 15) and whole stomach controls (n = 8) were cultured for 7 days. In addition, organ blocks were examined after normal development at days 4 to 10 (n = 4 for each stage). Tissues were analyzed using immunochemistry against quail-specific antigen and ISL-1.
RESULTS: Thirteen of 15 SM + PE recombinants expressed the ISL-1 protein in cells from SM origin. Nine of 15 of these recombinants showed iMET and coexpression of insulin, and ISL-1 was recorded.
CONCLUSIONS: Pancreatic epithelium is able to reprogram SM to a more caudal pancreatic fate when cocultured. Islet tissue by mesenchymal-to-epithelial transition observed in recombinants showed coexpression of insulin and ISL-1. These experiments are important to identify the molecular mechanisms behind iMET for potential therapeutic use for treating children with diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231532     DOI: 10.1016/j.jpedsurg.2008.10.085

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  1 in total

1.  Developmental stages of the Japanese quail.

Authors:  Sophie J Ainsworth; Rachael L Stanley; Darrell J R Evans
Journal:  J Anat       Date:  2009-11-19       Impact factor: 2.610

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.